



## COMPANY OVERVIEW

Cardax is a consumer health company focused on marketing ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health.\* Cardax previously focused on development of pharmaceuticals for diseases driven by inflammation. Cardax may seek to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration.

## RECENT NEWS

### Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded Study

Dec 6 2023, 3:00 PM EST

### Cardax Refocuses on ZanthoSyn® Consumer Health Business

Aug 31 2021, 6:18 PM EDT

## STOCK OVERVIEW

Symbol	CDXI
Exchange	OTCQB
Market Cap	3.21k
Last Price	\$0.004
52-Week Range	\$0.000001 - \$0.004

08/15/2025 02:48 PM EDT

## INVESTOR RELATIONS

Cardax, Inc.  
T: (808) 457-1400  
[investors@cardaxpharma.com](mailto:investors@cardaxpharma.com)

## MANAGEMENT TEAM

**David G. Watumull**  
Chairman and CEO

**David M. Watumull**  
COO and CFO

## CARDAX, INC.

2800 Woodlawn Drive  
Suite 129  
Honolulu, HI 96822

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.